杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/03/31 | 1,809 | 1,817 | 1,769 | 1,777 | -53 | -2.9% | 97,300 |
| 2022/03/30 | 1,844 | 1,851 | 1,813 | 1,830 | -48 | -2.6% | 79,800 |
| 2022/03/29 | 1,880 | 1,880 | 1,862 | 1,878 | -4 | -0.2% | 95,900 |
| 2022/03/28 | 1,907 | 1,907 | 1,872 | 1,882 | -1 | -0.1% | 82,200 |
| 2022/03/25 | 1,900 | 1,902 | 1,876 | 1,883 | +9 | +0.5% | 92,500 |
| 2022/03/24 | 1,886 | 1,893 | 1,857 | 1,874 | -27 | -1.4% | 106,300 |
| 2022/03/23 | 1,891 | 1,905 | 1,864 | 1,901 | +23 | +1.2% | 80,500 |
| 2022/03/22 | 1,897 | 1,897 | 1,866 | 1,878 | +3 | +0.2% | 122,700 |
| 2022/03/18 | 1,895 | 1,906 | 1,875 | 1,875 | -19 | -1% | 132,000 |
| 2022/03/17 | 1,917 | 1,917 | 1,885 | 1,894 | -5 | -0.3% | 93,800 |
| 2022/03/16 | 1,920 | 1,924 | 1,884 | 1,899 | -11 | -0.6% | 115,500 |
| 2022/03/15 | 1,878 | 1,912 | 1,872 | 1,910 | +32 | +1.7% | 90,900 |
| 2022/03/14 | 1,887 | 1,892 | 1,877 | 1,878 | +1 | +0.1% | 58,800 |
| 2022/03/11 | 1,873 | 1,891 | 1,866 | 1,877 | -9 | -0.5% | 106,300 |
| 2022/03/10 | 1,860 | 1,886 | 1,846 | 1,886 | +49 | +2.7% | 98,200 |
| 2022/03/09 | 1,817 | 1,838 | 1,805 | 1,837 | +27 | +1.5% | 57,200 |
| 2022/03/08 | 1,805 | 1,824 | 1,800 | 1,810 | +3 | +0.2% | 57,500 |
| 2022/03/07 | 1,802 | 1,817 | 1,787 | 1,807 | -5 | -0.3% | 61,000 |
| 2022/03/04 | 1,825 | 1,832 | 1,809 | 1,812 | -18 | -1% | 52,500 |
| 2022/03/03 | 1,831 | 1,849 | 1,820 | 1,830 | +26 | +1.4% | 50,700 |
| 2022/03/02 | 1,821 | 1,834 | 1,801 | 1,804 | -43 | -2.3% | 78,700 |
| 2022/03/01 | 1,880 | 1,880 | 1,843 | 1,847 | -26 | -1.4% | 61,500 |
| 2022/02/28 | 1,836 | 1,873 | 1,832 | 1,873 | +38 | +2.1% | 76,200 |
| 2022/02/25 | 1,850 | 1,850 | 1,818 | 1,835 | -12 | -0.6% | 72,000 |
| 2022/02/24 | 1,829 | 1,847 | 1,818 | 1,847 | +17 | +0.9% | 78,300 |
| 2022/02/22 | 1,830 | 1,840 | 1,820 | 1,830 | ±0 | ±0% | 48,600 |
| 2022/02/21 | 1,838 | 1,839 | 1,823 | 1,830 | -22 | -1.2% | 36,300 |
| 2022/02/18 | 1,843 | 1,856 | 1,836 | 1,852 | -1 | -0.1% | 40,800 |
| 2022/02/17 | 1,877 | 1,877 | 1,853 | 1,853 | -31 | -1.6% | 31,100 |
| 2022/02/16 | 1,876 | 1,884 | 1,861 | 1,884 | +26 | +1.4% | 45,000 |
| 2022/02/15 | 1,857 | 1,873 | 1,852 | 1,858 | ±0 | ±0% | 61,800 |
| 2022/02/14 | 1,853 | 1,864 | 1,842 | 1,858 | ±0 | ±0% | 56,900 |
| 2022/02/10 | 1,855 | 1,865 | 1,846 | 1,858 | +15 | +0.8% | 48,700 |
| 2022/02/09 | 1,847 | 1,853 | 1,836 | 1,843 | ±0 | ±0% | 52,000 |
| 2022/02/08 | 1,861 | 1,866 | 1,838 | 1,843 | -14 | -0.8% | 65,300 |
| 2022/02/07 | 1,848 | 1,865 | 1,834 | 1,857 | +3 | +0.2% | 98,000 |
| 2022/02/04 | 1,848 | 1,854 | 1,833 | 1,854 | +16 | +0.9% | 77,400 |
| 2022/02/03 | 1,832 | 1,847 | 1,822 | 1,838 | -3 | -0.2% | 83,800 |
| 2022/02/02 | 1,822 | 1,845 | 1,817 | 1,841 | +25 | +1.4% | 84,600 |
| 2022/02/01 | 1,826 | 1,828 | 1,806 | 1,816 | -6 | -0.3% | 72,000 |
| 2022/01/31 | 1,837 | 1,837 | 1,788 | 1,822 | -9 | -0.5% | 118,200 |
| 2022/01/28 | 1,812 | 1,831 | 1,812 | 1,831 | +39 | +2.2% | 80,700 |
| 2022/01/27 | 1,800 | 1,802 | 1,776 | 1,792 | -24 | -1.3% | 153,300 |
| 2022/01/26 | 1,835 | 1,835 | 1,810 | 1,816 | -22 | -1.2% | 49,100 |
| 2022/01/25 | 1,850 | 1,850 | 1,820 | 1,838 | -7 | -0.4% | 80,700 |
| 2022/01/24 | 1,803 | 1,849 | 1,803 | 1,845 | +24 | +1.3% | 79,800 |
| 2022/01/21 | 1,791 | 1,827 | 1,780 | 1,821 | +22 | +1.2% | 114,100 |
| 2022/01/20 | 1,826 | 1,826 | 1,792 | 1,799 | -16 | -0.9% | 122,700 |
| 2022/01/19 | 1,809 | 1,822 | 1,798 | 1,815 | -11 | -0.6% | 85,300 |
| 2022/01/18 | 1,847 | 1,852 | 1,825 | 1,826 | ±0 | ±0% | 82,800 |
651～
700
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| ＪＣＲファーマ | 72,400円 | -3.7% | -36.7% | 2.76% | 23.84倍 | 1.56倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| 栄研化 | 209,200円 | +0.4% | -8.4% | 2.53% | 27.65倍 | 1.57倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム
